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Abstract
Background: The expression level of cyclin D1 plays a vital role in the control of proliferation.
This protein is reported to be degraded following phosphorylation by glycogen synthase kinase 3
(GSK3) on Thr-286. We recently showed that phosphorylation of Thr-286 is responsible for a
decline in cyclin D1 levels during S phase, an event required for efficient DNA synthesis. These
studies were undertaken to test the possibility that phosphorylation by GSK3 is responsible for the
S phase specific decline in cyclin D1 levels, and that this event is regulated by the
phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway which controls GSK3.
Results: We found, however, that neither PI3K, AKT, GSK3, nor proliferative signaling activity in
general is responsible for the S phase decline in cyclin D1 levels. In fact, the activity of these signaling
kinases does not vary through the cell cycle of proliferating cells. Moreover, we found that GSK3
activity has little influence over cyclin D1 expression levels during any cell cycle phase. Inhibition of
GSK3 activity by siRNA, LiCl, or other chemical inhibitors failed to influence cyclin D1
phosphorylation on Thr-286, even though LiCl efficiently blocked phosphorylation of β-catenin, a
known substrate of GSK3. Likewise, the expression of a constitutively active GSK3 mutant protein
failed to influence cyclin D1 phosphorylation or total protein expression level.
Conclusion: Because we were unable to identify any proliferative signaling molecule or pathway
which is regulated through the cell cycle, or which is able to influence cyclin D1 levels, we conclude
that the suppression of cyclin D1 levels during S phase is regulated by cell cycle position rather than
signaling activity. We propose that this mechanism guarantees the decline in cyclin D1 levels during
each S phase; and that in so doing it reduces the likelihood that simple over expression of cyclin
D1 can lead to uncontrolled cell growth.
Background
Cyclin D1 plays a critical role in the regulation of prolifer-
ation by adjusting its expression levels to reflect the prolif-
erative signaling environment of the cell, and then by
regulating the cell cycle control machinery accordingly[1].
Cyclin D1 functions primarily to bind and activate the
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cyclin dependent kinase (CDK) 4/6, which then phospho-
rylates the retinoblastoma protein (Rb). Upon phosphor-
ylation Rb releases the transcription factor E2F, which is
then able to activate the transcription of genes required
for G1/S phase transition[2-5]. The cyclin D1/CDK4/6
complex is also able to sequester p27kip1 and other CDK
inhibitory proteins, thereby neutralizing their inhibitory
capacity for cyclin E/CDK2[6] whose activity is required
for G1/S transition[7,8].
The regulation of cyclin D1 activity is primarily dependent
upon its expression level. This level is controlled by the
regulation of gene expression, mRNA stability and trans-
lation, and by protein stability. Cyclin D1 mRNA synthe-
sis is regulated by mitogenic signaling pathways
downstream of Ras activity. These include the Raf-1,
MEK1/2 and ERKs pathways[9-11] ; along with the Ral
and Rac GTPases [12,13]. Translational control of cyclin
D1 is also under the control of growth factor signaling
through activation of the eukaryotic initiation factor 4E,
an effector of the phosphatidylinositol-3 kinase (PI3K)/
AKT/mTOR signal pathway [14]. The stability of cyclin D1
protein also plays a major role in the regulation of its
expression. Phosphorylation on Thr-286 has been
reported to result in rapid proteasomal degradation of
cyclin D1 [15]. It is also possible that this phosphoryla-
tion results in the export of cyclin D1 from the nucleus
where it is functionally inactivated due to separation from
its nuclear substrates [16]. In either case, the kinase
responsible has been reported to be glycogen synthase
kinase 3 (GSK3), which is an excellent in vitro kinase for
cyclin D1 Thr-286 [17]. GSK3 is presumed to be constitu-
tively active and therefore able to suppress cyclin D1 levels
until phosphorylated. This phosphorylation can be car-
ried out by AKT, which is in turn activated by PI3K
[18,19], suggesting that the PI3K/AKT/GSK3 pathway
controls cyclin D1 stability [15,17].
Not only are overall cyclin D1 levels critical in the growth
properties of the cell, the levels of this protein are actively
regulated through the cell cycle. We observed this fact
using quantitative image analysis of antibody stained
asynchronous cultures. Cyclin D1 expression was found
to be high in G1 and G2 phase cells, but fell to low levels
during S phase [20]. Subsequent studies have demon-
strated that this expression pattern is vital to the regula-
tion of ongoing cell cycle progression. The elevation of
cyclin D1 during G2 phase depends upon proliferative
signaling, and is required for the continuation of cell cycle
progression [21,22]. Suppression of cyclin D1 during S
phase is required for DNA synthesis, since high cyclin D1
levels are reported to bind PCNA and are able to block
DNA synthesis [23,24]. The requirement that cyclin D1
levels fall during S phase is likely to restrict the chance of
uncontrolled proliferation resulting simply from the ele-
vated expression of cyclin D1 [21]. Critically, we have
found that the specific suppression of cyclin D1 levels dur-
ing S phase is dependent upon phosphorylation of Thr-
286, since a mutation at this position blocked S phase cyc-
lin D1 suppression [24]. These studies were undertaken to
test the possibility, suggested by the above considerations,
that the phosphorylation on Thr-286 responsible for the
suppression of cyclin D1 during S phase is catalyzed by
GSK3.
If GSK3 were responsible for the S phase suppression of
cyclin D1, its activity would likely be lower during G1 and
G2 phases than during S phase. One mechanism for
achieving this cell cycle regulation of GSK3 activity would
be for the activities of PI3K and AKT to be modulated
through the cell cycle. There is a precedent for such cell
cycle variations in proliferative signaling. For example,
when oncogenic Ras is introduced into NIH3T3 cells, cyc-
lin D1 levels are rapidly induced, but only during G2
phase [25]. Moreover, signaling downstream of Ras activ-
ity suppresses p27Kip1 (p27) levels throughout the cell
cycle, but this is accomplished during each cell cycle phase
through the activation of separate signaling molecules
[26]. However, we find here that neither the activity of
proliferative signaling kinases nor of GSK3 itself varies
through the cell cycle. In fact, we find that GSK3 is not
responsible for the suppression of cyclin D1 levels during
S phase. Rather, we now postulate that cyclin D1 suppres-
sion during S phase is the result of cell cycle position
rather than proliferative signaling.
Results
The cyclin D1 expression pattern is not altered by signaling 
inhibitors
If the PI3K/AKT/GSK3 pathway stabilizes cyclin D1 levels
specifically during G1 and G2 phases as suggested above,
inhibitors of this pathway would produce a reduction in
cyclin D1 expression during these cell cycle phases to the
low levels seen during S phase. Thus, inhibition of these
signaling pathways would be expected to result in low,
uniform expression of cyclin D1 throughout the cell cycle.
PI3K was inhibited by LY294002, while the kinase mTOR
was inhibited by rapamycin in actively cycling human
diploid fibroblast (MRC5) cultures. After 2 hrs treatment,
including a terminal pulse with BrdU, the culture was
fixed and stained with fluorescent antibodies against both
cyclin D1 and BrdU, while DNA was stained with DAPI.
Individual images of each fluorochrome were collected
with a sensitive CCD camera, and subjected to image anal-
ysis to accurately quantitate the level of each fluoro-
chrome in each cell (see [20]). The results were displayed
by plotting the cyclin D1 level of each cell against its DNA
level, with BrdU positive cells noted (Fig. 1A). Treatment
with LY294002 dramatically reduced cyclin D1 levels, yet
the overall cell cycle pattern of expression was main-BMC Cell Biology 2006, 7:33 http://www.biomedcentral.com/1471-2121/7/33
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tained, with higher levels observed during G1 and G2
phases as in untreated cultures. Rapamycin had a similar
but weaker effect on the cyclin D1 level (Fig. 1A). Neither
inhibitor produced the uniform cyclin D1 expression
through the cell cycle we had predicted.
We next inhibited AKT activity by microinjecting a plas-
mid expressing a dominant inhibitory mutant. This plas-
mid, pCDNA3-Akt-DN (K179 M, a kind gift of Dr. Nissim
Hay) generates a kinase-dead AKT protein that can be
detected within the cells by antibody staining. Staining
confirmed the high level expression of the mutant protein
at 4 and 24 hrs following plasmid injection. This protein,
however, did not induce any obvious alteration in cyclin
D1 expression after 8 hrs (Fig. 2A). The average expression
levels of cyclin D1 in injected cells at 8 hrs (not shown)
and 24 hrs (Fig. 2B) confirmed that the there was no
change in the cyclin D1 profiles in cells expressing an
excess of inhibitory AKT protein.
It is possible that proliferative signaling molecules other
than those inhibited above might be responsible for S
phase cyclin D1 suppression. To test this possibility pro-
liferative signaling in general was disrupted by serum
withdrawal for 4 hrs. In this case, the level of Thr-286
phosphorylation of cyclin D1 was directly determined
with a phosphorylation site-specific antibody (the gener-
ous gift of Michelle D. Garrett and David R. Mason), and
compared to total cyclin D1. To avoid rapid degradation
of phosphorylated cyclin D1 [27], the cells were treated
with the proteasomal inhibitor MG132 for 2 hrs prior to
analysis. Serum withdrawal for 4 hrs slightly reduced both
total and Thr-286-phosphorylated cyclin D1. Signifi-
cantly, however, the ratio of phospho/total cyclin D1 was
not changed by serum deprivation in any cell cycle phase
(Fig. 1B). This indicates that the overall rate of cyclin D1
Thr-286 phosphorylation is not altered in any cell cycle
phase by disruption of proliferative signaling following
serum removal. Taken together, the above results fail to
support the notion that alterations in proliferative signal-
ing through the cell cycle are responsible for the cell cycle
specific expression pattern of cyclin D1.
The activity of critical signaling molecules remains 
constant through the cell cycle
To extend the above observations, we designed experi-
ments to directly analyze the activity of individual prolif-
erative signaling molecules through the cell cycle, to
determine if there are alterations in proliferative signaling
activity sufficient to account for the proposed variations in
GSK3 activity. We first analyzed the activity of PI3K in
individual cells of an asynchronous NIH3T3 culture using
a plasmid expressing the PH domain of AKT linked to GFP
[28]. T. Balla and associates have shown that the resulting
protein strongly binds phosphatidylinositol-3-phosphate,
the lipid product of PI3K activity, resulting in its associa-
tion with the plasma membrane upon activation of PI3K
[28]. To directly visualize the redistribution of fluores-
cence at the time of PI3K stimulation, the AKT-PH-GFP
plasmid was microinjected into quiescent NIH3T3 cells.
The intracellular distribution of fluorescence was deter-
mined by confocal analysis 15 hrs later without serum
addition, or 20 min following addition of 10% serum to
the culture. Without serum addition, the fluorescence was
uniformly distributed throughout the cytoplasm and
nucleus (Fig. 3B). Upon serum stimulation, however, the
fluorescence became associated with the plasma mem-
brane (Fig. 3A), including particularly high concentra-
tions associated with tiny projections on the plasma
membrane. Thus, the loss of fluorescence from the
nucleus and cytoplasm, coupled with its redistribution to
plasma membrane structures was diagnostic for PI3K
activity [see Additional file, movies 1, 2, 3].
This assay was then applied to actively cycling NIH3T3
cells, where we found that the fluorescence of all cells
remained evenly distributed throughout the cytoplasm
and nucleus. Specific association of fluorescence with the
plasma membrane was not observed in any of these cells
(Fig. 3C). To demonstrate that cycling cells did retain the
ability to produce a high level of PI3K activity, the PH-
AKT-GFP plasmid was injected into proliferating NIH3T3
cells, after which serum was removed from the culture for
5–12 hrs, and then added back. Within 20 minutes of the
addition of serum back to these cultures the fluorescence
became associated with the plasma membrane, character-
istic of PI3K activation described above for quiescent cells
(Fig. 3D–G).
These results present an interesting model of proliferative
signaling in cycling cells. The high levels of PI3K activity
observed following serum addition to quiescent cultures
most likely represents the response to a change in growth
condition rather than a normal consequence of cell cycle
progression. While PI3K activity is present in and required
for the proliferation of actively cycling cells, the levels
required are apparently much lower than observed upon
serum stimulation. Importantly, there was no evidence of
alterations in PI3K activity during S phase or any other cell
cycle period in asynchronous cultures, reducing the likeli-
hood that such an alteration might be responsible for the
elevation in GSK3 activity, and the corresponding decline
in cyclin D1 levels during S phase.
AKT is activated uniformly through S and G2 phases
The above study of individual cells in an actively cycling
culture was next confirmed by biochemical analyses in
synchronized cell populations. A single treatment of
NIH3T3 cells with 2 mM thymidine has been shown to
result in their synchronization in S phase. FollowingBMC Cell Biology 2006, 7:33 http://www.biomedcentral.com/1471-2121/7/33
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removal of thymidine, treated cells remain in S phase for
4 hrs, and enter G2 phase approximately 5 hrs later
[24,27]. Critically, we have confirmed that the cell cycle
expression profile of cyclin D1 in such synchronized cul-
tures behaves as in asynchronous cultures, with low levels
in S phase cells, followed by increasing levels upon entry
into G2 phase (see Fig. 4D). Cultures prior to or at various
times following release from thymidine blockage were
tested by western analysis for the activating phosphoryla-
tion of AKT (Fig. 4A,C), while cyclin D1 expression levels
are presented for comparison (Fig. 4B,D). No evidence of
alterations in the activation level of AKT was apparent at
any time following release from thymidine blockage, as
the cells passed from S to G2 phase. As a control, the levels
of the activating phosphorylation on AKT were seen to
increase dramatically within 15 and 90 min following
treatment of quiescent NIH3T3 cells with serum. Moreo-
ver, in the cultures which showed no difference in AKT
activation levels, the levels of cyclin D1 protein were seen
to increase during passage from S to G2 phase (as previ-
ously demonstrated [27]). We conclude that alteration in
the activity of AKT is not responsible for suppression of
cyclin D1 levels during S phase.
GSK3 activity is constant in synchronized S and G2 phase 
cells
From the above results it is clear that the proliferative sig-
naling pathway upstream of GSK3 does not vary through
the cell cycle. However, it is possible that a pathway other
than PI3K/AKT is responsible for regulation of GSK3 activ-
ity [29]. Therefore, antibody staining as well as biochem-
ical analyses were performed to directly study variation of
GSK3 activity through the cell cycle. NIH3T3 cells were
synchronized in S phase by thymidine treatment and
released as described above. Most of the cells progressed
from S to G2 phase 5 hours after the release. The cells were
collected at the indicated times, and the GSK3 phosphor-
ylation was analyzed by western analysis with an antibody
specific to the inhibitory phosphorylation of GSK3β on
position 9 (Fig. 5A, upper panel). Total GSK3 was also
Cyclin D1 expression following inhibitor treatment Figure 1
Cyclin D1 expression following inhibitor treatment: (A) MRC5 cells were left untreated (left) or were treated with 20 μM 
LY294002 (middle) to inhibit PI3K or 50 nM rapamycin (right) to inhibit mTOR. After 2 hrs cyclin D1, BrdU added as a final 
pulse, and DNA were stained and subjected to image analysis. Cyclin D1 levels for individual cells are plotted vs. DNA levels, 
with BrdU positive, S phase cells shown as small, solid circles; with cell cycle phases noted. (B) Serum was removed from 
NIH3T3 cultures for 4 hrs, after which cells were fixed and stained for total cyclin D1 and with an antibody able to recognize 
phospho-Thr-286 cyclin D1. The average cyclin D1 (left) or phospho-Thr-286 cyclin D1 (middle) for each cell cycle phase was 
determined and plotted (darker bars), together with the similar value determined from a parallel culture maintained in serum 
(lighter bars). Finally (right) the ratio of phospho-cyclin D1 to total cyclin D1 is presented for both the normal and serum 
deprived culture.
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Dominant inhibitory AKT and cyclin D1 expression Figure 2
Dominant inhibitory AKT and cyclin D1 expression: (A) A plasmid expressing dominant inhibitory AKT was microinjected into 
NIH3T3 cells at the left of the area shown. The cells were incubated 8 hrs, fixed and stained with a fluorescent antibody stain 
against cyclin D1 (top), AKT (middle), or with DAPI to stain DNA (bottom). The same area of cells is shown in each frame. (B) 
NIH3T3 cells were injected with the inhibitory AKT plasmid 24 hrs prior to fixation and staining as above. Injected and unin-
jected cells were identified by staining for AKT, and cells were divided into cell cycle phase according to BrdU labeling and 
DNA content. The average cyclin D1 levels are shown for each group of cells.
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PI3K activity through the cell cycle Figure 3
PI3K activity through the cell cycle. NIH3T3 cells were deprived of serum for approximately 30 hrs and injected with the PH-
AKT-GFP plasmid. 15 hrs later cells were photographed under confocal microscopy either 20 min following serum stimulation 
(A), or without stimulation (B). Similarly, (C) cycling NIH3T3 cells were injected with the plasmid and photographed 15 hrs 
later. To confirm that the cycling cells retained the ability to stimulate PI3K activity, they were injected with the plasmid and 
deprived of serum for 0 hr (D), 5 hrs (E), 9 hrs (F) or 12 hrs (G) prior to addition of serum 20 min before confocal microscopy. 
Note the concentrations of fluorescence in cytoplasmic projections (E, F) or uniformly over the plasma membrane (G) follow-
ing serum stimulation. The appearance of stimulated cells is clearly illustrated in a complete series of confocal sections at vary-
ing magnifications [presented in Additional files, movies 1, 2, 3].BMC Cell Biology 2006, 7:33 http://www.biomedcentral.com/1471-2121/7/33
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determined and the phospho-GSK3/total GSK3 ratio pre-
sented (Fig. 5A, lower panel). We next directly determined
the activity of GSK3 by synchronizing cells as described
above, and immunoprecipitating GSK3 at the indicated
times following release. The immunoprecipitated protein
was then assayed with a synthetic peptide substrate whose
phosphorylation was analyzed by PAGE analysis. Due to
the low level of activity of GSK3 in NIH3T3 cells, this
assay was repeated 10 times to obtain consistent results
(Fig. 5B). There was some increase in GSK3 activity imme-
diately upon release from thymidine blockage, but no evi-
dence of any alteration upon passage from S to G2 phase.
AKT activity in S and G2 phases Figure 4
AKT activity in S and G2 phases: (A) NIH3T3 cells were synchronized with thymidine treatment in S phase and released by thy-
midine removal for the indicated times. In addition, quiescent cells were left unstimulated (G0), or stimulated with serum for 
the indicated times. In each case, lysates were collected and probed with an antibody specific for the activating phosphorylation 
on AKT. This was compared to western analysis of total AKT protein. Cells enter G2 phase 4–5 hrs following thymidine 
removal. (C) The levels were quantitated, and the ratio of phospho-specific AKT divided by total AKT levels is presented. (B) 
For comparison, the levels of cyclin D1 were analyzed by western analysis in the same lysates, (D) and quantitated.
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For comparison, there was a reduction in activity upon
addition of serum to quiescent cultures, while the levels of
GSK3 activity declined only gradually following serum
removal from actively cycling cultures [see Additional file
4]. As a control, the inhibition of GSK3 activity by 50 mM
LiCl is demonstrated (Fig. 5B). It is clear from these results
than neither the upstream signaling pathway leading to
GSK3 control, nor the activity of GSK3 itself varies during
passage from S to G2 phase in synchronized cultures, or in
actively cycling cells. This places doubt on the role of pro-
liferative signaling or GSK3 activity in suppressing cyclin
D1 levels during S phase.
Inhibition of GSK3 activity has no effect upon cyclin D1 
expression
Experiments were next designed to determine if GSK3
activity plays a role in cyclin D1 expression or phosphor-
ylation in any cell cycle phase. GSK3 activity was inhibited
by 25 mM LiCl, and the proteasomal inhibitor MG132
was added to allow the accumulation of phosphorylated
cyclin D1. To determine if the inhibition of GSK3 would
reduce the phosphorylation of cyclin D1, the effect of this
treatment upon phospho-Thr-286 accumulation was
determined by image analysis following staining with the
phospho-Thr-286-specific antibody [27]. LiCl influenced
neither the total amount of cyclin D1 nor its level of phos-
phorylation following staining of human diploid fibro-
blast MRC5 cells. This is apparent from the cell cycle
expression profiles (Fig. 6A), and from average levels
determined from these profiles (Fig. 6B). To confirm the
results with LiCl, we performed similar experiments on
NIH3T3 cells with two other GSK3β inhibitors, sodium
valproate [30] and GSK3 inhibitor II from Calbiochem.
Neither of these treatments altered the ratio of total cyclin
D1 to phosphorylated cyclin D1 (Fig. 6C).
This critical result was next confirmed by western analysis.
NIH3T3 cultures were treated with medium containing 25
mM or 50 mM LiCl to inhibit GSK3 activity, or with
medium containing equivalent amounts of NaCl as a con-
trol. MG132 was added to block degradation of phospho-
rylated proteins as above. After treatment for 4 hrs the
levels of total and phosphorylated β-catenin were deter-
mined by western analysis with appropriate antibodies,
while actin was analyzed as a loading control. β-catenin is
a well characterized substrate of GSK3. Its phosphoryla-
tion would, therefore, serve as an indication of the activity
of GSK3 within the treated cells. Since the lysate was not
separated into nuclear and cytoplasmic fractions [31,32],
little alteration in the total β-catenin levels were seen (Fig.
7A). On the other hand, high levels of phosphorylated β-
catenin were observed in cells cultured in normal medium
(Fig. 7 column 2). Phosphorylated β-catenin levels were
dramatically reduced by 25 mM LiCl (Fig. 7 column 3)
and almost completely eliminated by treatment with 50
mM LiCl (Fig. 7 column 5). Levels of the phosphorylated
proteins were observed only when their degradation was
blocked by treatment with the proteasome inhibitor,
MG132 (Fig. 7 columns 3, 4). The results were confirmed
by quantitating the ratio of phosphorylated to total β-cat-
enin (Fig. 7C). On the other hand, in these same lysates
neither concentration of LiCl had any effect upon the
phosphorylation of cyclin D1 on Thr-286 (Fig. 7 column
3, 5). This conclusion was confirmed following quantita-
tion of the western bands to determine the ratio of phos-
phorylated to total cyclin D1 levels (Fig. 7B). The fact that
LiCl was able to block the phosphorylation of a well
known GSK3 substrate, without influencing the phospho-
rylation of cyclin D1within the same cells, confirms the
above conclusion that GSK3 is not a major kinase for cyc-
lin D1 in these cells.
To strengthen this conclusion, GSK3 protein was ablated
with a commercial siRNA mixture reported to suppress
levels of both GSK3 α and GSK3β. To confirm its effective-
ness, this siRNA was injected into NIH3T3 cells 12 hrs
prior to a second injection of a plasmid expressing the
GSK3 β gene (the gift of J. R. Woodgett). Following these
injections the cells were fixed and stained with a fluores-
cent antibody stain against GSK3. While the plasmid
expressed high levels of GSK3 when injected alone (Fig.
8A), prior injection with siRNA totally blocked expression
of the high exogenous levels of GSK3 (Fig. 8B). Even
though the endogenous levels of GSK3 are low, these
endogenous levels were also suppressed by the injected
siRNA (Fig. 8B). We conclude that the siRNA is able to
efficiently ablate GSK3 expression. This siRNA was
injected into NIH3T3 cells, which were left over night
prior to treatment with MG132 and staining with the
phospho-Thr-286 cyclin D1 antibody. The siRNA had no
influence upon phosphorylation of cyclin D1 (Fig. 8C), or
upon total cyclin D1 levels (not shown). We conclude that
inhibition of GSK3 does not alter normal cell cycle regu-
lated phosphorylation of cyclin D1.
Over-expression of activated GSK3 β does not suppress 
cyclin D1 levels
The influence of GSK3 upon cyclin D1 degradation in
NIH3T3 and MRC5 cells was next directly analyzed by
microinjection of a plasmid expressing a constitutively
active GSK3 β protein (S9A: the gift of J. R. Woodgett)
[33,34]. Injected cells were stained for GSK3 and cyclin
D1 at 8 and 24 hrs following injection. GSK3 staining was
strong in injected cells at both time points, and displayed
a cytoplasmic localization in most of the cells; whereas
the staining was close to background level in the unin-
jected cells, indicating that the exogenous GSK3 level is far
above the endogenous level (Figure 9A). However, the
exogenous, constitutively active GSK3β did not appar-BMC Cell Biology 2006, 7:33 http://www.biomedcentral.com/1471-2121/7/33
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GSK3 activity does not vary between S and G2 phases: NIH3T3 cells were synchronized with thymidine treatment and  released by thymidine removal for the indicated times Figure 5
GSK3 activity does not vary between S and G2 phases: NIH3T3 cells were synchronized with thymidine treatment and 
released by thymidine removal for the indicated times. Cells remain in S phase for the first four hrs after thymidine removal 
and then enter G2 phase thereafter. (A) Cell lysates were collected at the indicated times following thymidine removal, and 
subjected to Western analysis for GSK3β phosphorylated on position 9, together with total GSK3 levels (upper panel). The 
results were quantitated, and the ratio of phosphorylate to non-phosphorylate GSK3 is presented (lower panel). (B) GSK3 
protein was immunoprecipitated from cell lysates collected at the indicated times following thymidine release and the GSK3 
protein assayed for kinase activity against a synthetic substrate. This figure represents the combined results of 10 different anal-
yses, normalized to the level of GSK3 activity in thymidine-blocked cells. For comparison, S phase lysates were treated with 50 
mM LiCl.
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Inhibition of GSK3 does not alter cyclin D1 levels Figure 6
Inhibition of GSK3 does not alter cyclin D1 levels: (A) MRC5 cells were treated for 3 hrs with MG132 alone, or in combination 
with 25 mM LiCl. The cells were then fixed and the level of cyclin D1 (left), or the level of phospho-Thr-286 cyclin D1 (right), 
for each cell was determined by image analysis and plotted against its level of DNA (with BrdU positive cells indicated as small, 
closed circles). (B) In an analogous experiment, MRC5 cells were treated with the indicated concentration of LiCl together 
with MG132. After 3 hrs the average level of phospho-Thr-286 cyclin D1 in each cell cycle phase was determined for each LiCl 
concentration indicated (0, 12.5, of 25 mM). (C) NIH3T3 cells were treated with MG132 together with 25 mM valproate (V), 
with 25 μM GSK3 inhibitor II (II), or with no treatment as a control (C). The average levels of phospho-Thr-286 cyclin D1 in 
each cell cycle phase of each treatment is shown.
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LiCl inhibits phosphorylation of β-catenin but not cyclin D1: NIH3T3 cells were cultured in medium containing 25 mM LiCl  (columns 3, 4), 50 mM LiCl (column 5), or control medium with NaCl (columns 1, 2) Figure 7
LiCl inhibits phosphorylation of β-catenin but not cyclin D1: NIH3T3 cells were cultured in medium containing 25 mM LiCl 
(columns 3, 4), 50 mM LiCl (column 5), or control medium with NaCl (columns 1, 2). In some cultures MG132 was added to 
block degradation of phosphorylated proteins (columns 2, 3, 5; see legend at the top). After 4 hrs lysates were prepared and 
probed for β-catenin, β-catenin phosphorylated on Ser 33/37/Thr 41, cyclin D1, cyclin D1 phosphorylated on Thr-286, and for 
actin as a loading control. (A) Photographs of the western results are presented. Each band was then quantitated, and (B) the 
ratio of phosphorylated cyclin D1 divided by the level of total cyclin D1 protein was determined and plotted immediately 
below the corresponding western bands. In addition, (C) the ratio of phosphorylated β-catenin divided by the level of total β-
catenin protein is presented. Quantitative results correspond to the bands displayed in this figure immediately above them 
(with the same lane numbers).
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siRNA against GSK3 does not influence cyclin D1 phosphorylation Figure 8
siRNA against GSK3 does not influence cyclin D1 phosphorylation: (A) A vector expressing activated GSK3β protein was 
injected into an NIH3T3 plate within a circular area marked on the back of the coverslip and indicated in the photographs 
above. (B) A similar injection of GSK3β was preceded 15 hrs earlier with an injection of an siRNA mixture against GSK3 α and 
GSK3 β. 5 hrs after these GSK3 plasmid injections cells were fixed and the GSK3 stained with a fluorescent antibody stain. The 
fluorescence photographs of each injection are presented. (C) To determine the influence of reduced GSK3 expression on the 
phosphorylation of cyclin D1, this siRNA was microinjected 15 hrs prior to a pulse with BrdU, fixation and staining for phos-
pho-Thr-286 cyclin D1, BrdU and DNA. The average phospho-Thr-286 cyclin D1 levels in each cell cycle phase of injected, or 
neighboring uninjected cells is presented. MG132 was added 2 hrs prior to fixation to preserve phosphorylated cyclin D1 as 
above.
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ently alter cyclin D1 levels at 8 hrs (Fig. 9A) or 24 hrs (not
shown) following injection.
The effect of injected GSK3β upon cyclin D1 expression
was next analyzed quantitatively. At 8 hrs following injec-
tion of the GSK3β expression plasmid cells were fixed and
stained with fluorescent antibodies against cyclin D1 and
GSK3. The intensity of each stain in each cell was deter-
mined by quantitative image analysis, and the GSK3 levels
were plotted vs. cyclin D1 levels (Fig. 9B). The basal cyclin
D1 level was apparent from the analysis of uninjected
cells. This level of cyclin D1 expression was altered little if
at all in cells containing even high levels of exogenous
GSK3β. We conclude that GSK3β has little influence over
cyclin D1 levels in NIH3T3 cells 8 hrs following injection.
Similar results were obtained at 24 hrs in NIH3T3 cells,
and in MRC5 cells (not shown). Finally, the average
expression level of phospho-Thr-286 cyclin D1 was deter-
mined in each cell cycle phase following injection of the
GSK3β plasmid as above, and compared to uninjected
cells. In no case was there any difference between injected
and uninjected cells in the level of phospho-Thr-286 cyc-
lin D1 (Fig. 9C).
GSK3 is potentially involved in G2 phase
The above experiments show no evidence for the involve-
ment of GSK3 in cyclin D1 expression or phosphorylation
in any cell cycle phase. It should be emphasized, however,
that all of those studies were performed upon cells cul-
tured with normal growth factors which might have
induced proliferative signaling within the cells to neutral-
ize all GSK3 activity, thereby masking its potential role in
regulating cyclin D1 in the absence of serum. This possi-
bility is supported by the fact that while cyclin D1 sup-
pression following serum removal is primarily due to
reduced mRNA stability, there is also evidence for a lim-
ited role of altered protein stability upon serum removal
[24]. To test the possibility that GSK3 might play a role in
cyclin D1 regulation in the absence of serum, NIH3T3
cells were given a brief pulse of BrdU prior to serum
removal for 11 hrs. Thus, cells in S phase at the time of
serum removal would be labeled with BrdU. It is known
that these cells would progress normally through mitosis,
but with low cyclin D1 levels [22]. To determine if GSK3
might play a role in maintaining cyclin D1 at low levels in
these serum-deprived cells, they were treated with 12.5 or
25 mM LiCl to inhibit GSK3 activity at the time of serum
removal. Our attention was focused upon the BrdU
labeled cells to determine if their cyclin D1 levels
remained low upon entry into G2 phase. The addition of
12.5 mM LiCl failed to alter cyclin D1 levels, but 25 mM
LiCl treatment resulted in the elevation of cyclin D1 levels
in some of the cells passing from S to G2 phase in the
absence of serum (Fig. 10A). Three duplicate experiments
were performed and compared to demonstrate a signifi-
cant increase in G2 phase cyclin D1 levels in serum
deprived cells cultured with 25 mM LiCl (Fig. 10B). We
interpret this result as potential evidence for a limited role
of GSK3 in regulating G2 phase levels of cyclin D1, partic-
ularly when proliferative signaling is limited. This conclu-
sion, however, is complicated by the fact that 25 mM LiCl
slowed passage of cells into mitosis, resulting in an
extended G2 phase (see Fig. 10A). We do not know if this
extended G2 length might contribute to the slight eleva-
tion of cyclin D1 levels induced by LiCl in this experi-
ment.
Discussion
The fact that cyclin D1 levels are suppressed during S
phase as a result of phosphorylation on Thr-286 [27] sug-
gests that the kinase responsible might be GSK3 (see
[15,17]). If GSK3 were responsible for the cell cycle spe-
cific suppression of cyclin D1 levels, the activity of this
kinase and those signaling molecules which regulate its
activity would be expected to vary in activity through the
cell cycle. Thus, inhibition of these signaling molecules
would be expected to abolish the cell cycle variations in
cyclin D1 levels. We found, however, that inhibitors of
PI3K, rapamycin and serum removal all suppressed cyclin
D1 levels, but that this suppression was uniform through
the cell cycle. The typical cell cycle expression pattern of
cyclin D1 was not altered by any of these treatments.
Moreover, cyclin D1 expression was not significantly sup-
pressed in any cell cycle phase by expression of a domi-
nant inhibitory AKT mutant protein, which is able to
directly regulate GSK3 activity. These results fail to sup-
port the notion that these signaling molecules are respon-
sible for specific suppression of cyclin D1 during S phase.
To extend this result, the activity of signaling molecules
was tested throughout the cell cycle. PI3K activity was
assessed in individual cells with a GFP chimeric protein
able to bind phosphatidylinositol-3 phosphate. The acti-
vating phosphorylation of AKT and the inactivating phos-
phorylation of GSK3β, together with the enzymatic
activity of total GSK3, were assessed biochemically in syn-
chronized populations. There was no evidence that any of
these signaling activities vary thorough the normal cell
cycle.
These results not only raise questions regarding the role of
proliferative signaling in regulating cyclin D1 levels
through the cell cycle, they bring into question the overall
role of GSK3 in regulating cyclin D1 levels in living cells
in general. To directly analyze the involvement of GSK3 in
the control of cyclin D1 levels, its activity was inhibited by
a variety of small molecule inhibitors, while its cellular
levels were suppressed by siRNA. In no case was there any
quantitative change in cyclin D1 levels in any cell cycle
phase. LiCl failed to alter the phosphorylation of cyclin
D1 on Thr-286 even though it efficiently blocked phos-BMC Cell Biology 2006, 7:33 http://www.biomedcentral.com/1471-2121/7/33
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Activated GSK3 does not alter cyclin D1 levels: (A) A plasmid expressing an activated mutant of GSK3β was microinjected into  the NIH3T3 cells at the right side of the area of cells photographed Figure 9
Activated GSK3 does not alter cyclin D1 levels: (A) A plasmid expressing an activated mutant of GSK3β was microinjected into 
the NIH3T3 cells at the right side of the area of cells photographed. 8 hrs following injection the cells were fixed and stained 
for GSK3, cyclin D1 and DNA. Separate fluorescence photographs of the same area of cells for of each fluorochrome are pre-
sented. (B) An injection of the GSK3 plasmid into NIH3T3 cells as above was performed and the expression of GSK3 deter-
mined by image analysis and plotted vs. the level of cyclin D1 in each cell. Injected cells are shown as small, solid circles. (C) An 
injection as described above was performed, but the cells were treated with MG132, and stained for phospho-Thr-286 cyclin 
D1 and BrdU. The average levels of phospho-cyclin D1 are plotted for each cell cycle phase for injected and neighboring unin-
jected cells.
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GSK3 regulation of cyclin D1 expression in the absence of serum: NIH3T3 cells were cultured in the indicated medium, follow- ing an initial pulse with BrdU Figure 10
GSK3 regulation of cyclin D1 expression in the absence of serum: NIH3T3 cells were cultured in the indicated medium, follow-
ing an initial pulse with BrdU. After 11 hrs the cells were fixed, stained and analyzed. (A) The cyclin D1 level of each cells is 
plotted vs. its DNA content, but only cells labeled with BrdU, and therefore in S phase at the beginning of the treatment period 
are displayed. (B) Three identical experiments were performed and the average level of cyclin D1 in G2 phase cells following all 
treatments is presented. For this analysis the value for serum-deprived cells was set at 1.0, and the relative expression levels 
following other treatments is displayed.
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phorylation of β-catenin in the same cells. Finally, consti-
tutively activated GSK3 β was introduced into living cells
and found to have no influence upon cyclin D1 levels. We
conclude that GSK3 does not play a role in the suppres-
sion of cyclin D1 during S phase, and that it is unlikely to
be involved in the regulating cyclin D1 levels in the
nucleus during any cell cycle phase. The one potential
uncertainty with these results is the fact that in all the
above experiments the cells were in the presence of nor-
mal serum levels. These might promote the constant sup-
pression of GSK3 activity in these cells, masking the
potential involvement of this enzyme in cyclin D1 regula-
tion in the absence of proliferative signaling. In a final
analysis, serum was removed from cycling NIH3T3 cells to
allow GSK3 to become active, and then in some cultures
it was again inhibited by the addition of LiCl. There was a
slight, if minor elevation of cyclin D1 in a small propor-
tion of G2 phase cells in the serum-deprived cultures
treated with LiCl. It is not clear, however, if this was the
direct result of cyclin D1 phosphorylation by GSK3, or the
ability of GSK3 to interfere with passage through G2
phase.
The possibility that GSK3 might have an effect upon cell
cycle progression is supported by its ability to influence a
variety of cellular processes in addition to insulin and gly-
cogen metabolism. It is directly involved in regulating cell
proliferation and survival [33,34]. GSK3 is also able to
phosphorylate transcription factors involved in growth
regulation, including c-Myc, c-Jun and c-Myb [35]; and
has been implicated in the action of growth factors on
neural cell growth [36]. It is also able to regulate develop-
ment directly [37], and as a member of the Wnt signaling
pathway [38-41]. GSK3 is able to phosphorylate the Tau
protein, involved in Alzheimer's disease [42]; play a role
in mitotic spindle function [43]; repress Hedgehog signal-
ing [44], and regulate cyclin E stability [45]. Recent studies
implicate its action in cell polarity determination [46].
The results presented here suggest that the ability of GSK3
to phosphorylate a protein in vitro might not indicate that
it has a role in the normal regulation of that protein
within a living cell [47,48]. This conclusion, however,
should be considered cautiously in cases where cell based
assays indicate a connection between GSK3 and the regu-
lation of a cellular protein [45].
Even though GSK3 has been implicated in a number of
regulatory pathways, our view of GSK3 as a modulator of
a wide variety of cellular processes must be reconsidered
in light of recent genetic studies. With a reverse genetics
approach in Drosophila, the inhibitory phosphorylation of
GSK3 was shown to play a critical role in the action of the
insulin/PI3K pathway, but was not involved in the stimu-
lation of growth by PI3K [40]. In addition, knock-in stud-
ies in mice with homozygous activating mutations of both
GSK3α and GSK3β demonstrated that while glycogen
metabolism was altered in some tissues, the animals were
otherwise normal in growth and development [41]. While
developmental alterations can mask the normal role of a
mutant protein, these studies emphasize the importance
of carefully analyzing the role of GSK3 in signaling proc-
esses. In the studies reported here, we find that despite the
fact that GSK3 is able to phosphorylate cyclin D1 on Thr-
286 [15], this molecule does not play a role in the cell
cycle regulated expression of cyclin D1. Our evidence fur-
ther suggests that it may not play any major role in the
expression of cyclin D1 in human and murine fibroblast
cells. The possibility remains that GSK3 plays some role in
other cell types, particularly during the growth factor
induced increase in nuclear cyclin D1 during G2 phase. It
has been shown, however, that ubiquitination of cyclin
D1 can efficiently take place following phosphorylation
of another site [49], or without the apparent requirement
for phosphorylation [50,51]. Consistent with this conclu-
sion, studies by others demonstrated that Thr-286 does
not play a major role in the overall regulation of cyclin D1
levels in a variety of cells, although it is reported to play a
role in the intracellular localization of this protein
through the cell cycle [52]. Our studies on intracellular
localization of cyclin D1 with the use of quantitative
image analysis, however, have failed to produce any evi-
dence of relocation from the nucleus to the cytoplasm
during passage into S phase [20].
Conclusion
These studies demonstrate that while the PI3K/AKT path-
way plays a critical role in progression through the cell
cycle, its activity in cycling cells is relatively low compared
serum stimulated cells, and is invariant through the cell
cycle. The cell cycle-specific effects of this signaling path-
way reported previously [25,26], therefore, must result
from the differences in the way target proteins are effected
during different cell cycle phases. It is, thus, clear that the
suppression of cyclin D1 during S phase is not the result
of altered signaling during this cell cycle period. We con-
clude that increased phosphorylation of Thr-286 and
reduced cyclin D1 stability are regulated by factors that are
present throughout S phase, and in no other cell cycle
period. This implies that the suppression of cyclin D1 lev-
els during S phase will take place in every S phase regard-
less of the signaling environment of the cell, or the activity
of any particular signaling molecule. This suppression not
only allows the cell to actively synthesize DNA [23,27],
but ensures that upon entry into G2 phase cyclin D1 levels
are always low. Since the continuation of proliferation
depends upon high levels of cyclin D1 during G2 phase, it
would thus be necessary that the cell induce cyclin D1 lev-
els each time it enters G2 phase if it is to continue prolif-
erating. Thus, the apparently automatic suppression of
cyclin D1 during each S phase ensures that signalingBMC Cell Biology 2006, 7:33 http://www.biomedcentral.com/1471-2121/7/33
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events of the previous cell cycle are erased, and forces the
cell to re-evaluate the proliferative signaling environment
prior to entry into the next cell cycle. These observations
also have implications for tumor formation. Elevated cyc-
lin D1 levels clearly play a central role in the stimulation
of proliferation. It is possible that the simple over expres-
sion of cyclin D1, therefore, might lead to uncontrolled
cell growth. The fact that its levels must decline during
each S phase, however, limits the extent to which cyclin
D1 levels can increase. Thus, since cyclin D1 has both pos-
itive and negative proliferative influences during different
cell cycle phases, its regulation must remain relatively nor-
mal for cell growth to take place at all. This places severe
limitations upon the extent to which a tumor cell can sim-
ply alter cyclin D1 levels as a means to achieve unre-
strained growth properties [21].
Methods
Reagents
NIH3T3 and MRC5 cells used in the experiments were
obtained from the American Type Culture Collection.
Mouse monoclonal (72–13G) and rabbit polyclonal (H-
295), anti-cyclin D1 antibodies were obtained from Santa
Cruz Biotechnology, while a rabbit monoclonal anti-cyc-
lin D1 was purchased from NeoMarkers Inc. Mouse anti-
GSK3β and anti-PKBα/Akt antibodies were purchased
from Transduction Laboratories. Phospho-GSK-3β (Ser9)
antibody, GSK-3α/β siRNA was purchased from Cell Sig-
naling Technology. Phospho-PKBα/Akt (Ser473) anti-
body was purchased from Promega. Anti-HA-fluorescein
antibody was obtained from Roche. The rabbit polyclonal
anti-phospho T-286 cyclin D1 antibody was raised as
described previously [27], and was the generous gift of M.
Garrett, or also purchased from Cell Signaling Inc. Mouse
monoclonal anti-β-catenin was from BD Biosciences
Pharmingen Inc., while rabbit polyclonal anti-phospho-
β-catenin was from Cell Signaling Inc, and recognizes Ser
33/34 and Thr 41.
A plasmid expressing HA-tagged wild-type GSK3β was a
kind gift of Dr. James R. Woodgett. A derivative plasmid
expressing HA-tagged mutant GSK3β (S9A) was generated
using QuikChange Multi Site-Directed Mutagenesis Kit
(Stratagene). The plasmid pCDNA3-Akt-DN that
expresses the dominant-negative form of AKT (K179 M)
was kindly provided by Dr. Nissim Hay. The proteasomal
inhibitor MG132, BrdU and sodium valproate were pur-
chased from Sigma-Aldrich. LY294002, rapamycin, and
GSK3 inhibitor II were obtained from CalBiochem. GSK3
Substrate (Phospho-Glycogen synthase peptide-2) and
GSK3 non-substrate peptide (glycogen synthase peptide-2
(Ala21)) were purchased from Upstate Biotechnology.
Cell culture
NIH3T3 mouse fibroblast cells were grown in DMEM
medium supplied with 10% bovine calf serum. MRC5
human fibroblast cells were cultured in DMEM with 10%
fetal calf serum. The cells used in all experiments were
maintained at no more than 70% confluence. For S phase
synchronization, NIH3T3 cells were cultured in growth
medium containing 2 mM thymidine for approximately
14 h. To release the cells from the blockage, the monol-
ayer was washed twice with PBS (37°C), then cultured
with 10% bovine serum-containing DMEM for the indi-
cated periods of time. Judging by the DNA content, BrdU
labeling, and the incidence of mitotic figures, the culture
was most enriched in G2 population around 5 h after the
release. For G1 phase synchronization, NIH3T3 cells were
serum-starved with 0.5% serum-containing DMEM for 48
h. The quiescent cells were stimulated to enter G1 phase
by replacing the serum-deficient medium with 10%
serum-containing medium. In the case were cells were
treated with LiCl and MG132 together, the cells were pre-
treated with LiCl for 15 minutes prior to addition of
Mg132. Immunostaining procedures, kinase assay, and
western blot analysis are described in the Additional files.
Imaging
Digital images were collected with a cooled, monochrome
camera (800 × 1000 pixels) from Roper Scientic with Met-
amorph software (Universal Imaging) at 200 magnica-
tion. The processing of images has been described [20].
Filter systems were designed by Chroma for the indicated
fluorochrome. In summary, images of each fluorochrome
were collected of the same area of the culture. Images of
uniformly stained specimens were also photographed and
used to shade the images collected, to correct for non-uni-
form illumination of the sample. After shading, the DAPI
image was threshholded to identify the nuclei of each
individual cell, and the resulting image used as a mask to
measure the shaded images of each fluorochrome. Thus,
the fluorescent intensity of each fluorochrome for each
cell was identified. Results presented result from 100–
2000 individual cells. Normally approximately 150–300
cells were injected for each experiment. S phase cells were
identified as those labeled with BrdU, while G1 and G2
phase cells were BrdU negative and distinguished by DNA
content. BrdU was added for 20–30 min as a pulse (5-
Bromo-2'-deoxyuridine, Boehringer stock solution).
Confocal and time-lapse analysis
Confocal analysis of GFP expression was performed with
a Leica instrument on living cultures. The injected cells
were identified by a circular mark on the back of the cov-
erslip. Cells were localized under normal illumination so
that illumination for confocal analysis would require a
minimal exposure to laser light. The cells were mounted
under a coverslip in the indicate medium and the proce-BMC Cell Biology 2006, 7:33 http://www.biomedcentral.com/1471-2121/7/33
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dure normally completed within 10 minutes. For fluores-
cence time-lapse, images were taken for 200 milliseconds
every 1–2 hrs. This exposure did not interfere with the
normal proliferation of the cells.
Additional methods for additional files
Immunofluorensce staining of cyclin D1 and BrdU in monolayer cells
NIH3T3 at 50% confluence on coverslips were fixed with
100% methanol at room temperature for 15 minutes. The
coverslips were washed with PBS two times and blocked
with blocking buffer (1% of BSA in PBS) for 4 hours. For
staining and image quantitation of cyclin D1, the method
was that detailed previously [20]. Briefly, the blocked cov-
erslips were incubated with cyclin D1 antibody (1:50 dilu-
tion) at 4C overnight, followed by three washes of PBS.
The secondary antibody coupled with fluorochome
(1:1000 dilution) was applied to coverslips at 37C for 3
hours at 4C overnight. Coverslips were then washed 3
times with PBS. BrdU staining was performed as previ-
ously described [53]. The coverslips were re-fixed with
100% methanol followed by two washes with PBS-0.5%
Tween-20 and two washes of distilled water. Treatment of
1.5 NHCl was then applied to coverslips at room temper-
ature for 10 minutes followed by two washes of PBS-0.5%
Tween-20 at pH 7. The coverslips were re-blocked with
CAS block solution (ZYMED) at room temperature for 2–
4 hours, followed by incubation with BrdU antibody
(1:300 dilution) at 4C overnight. After 3 PBS-Tween-20
washes coverslips were incubated with secondary anti-
body coupled with Cy5 in 0.3% BSA in PBS at 4C over-
night. Further three washes were required before
performing DAPI staining for DNA content.
Kinase activity assays of GSK3
Kinase activity assay of GSK3 was done according to X.
Fang et al. [29]. 60–70% confluent NIH 3T3 cells treated
as indicated in the text were washed with cold PBS,
scraped and collected in Eppendorf tubes. The cell pellets
were snap frozen in liquid N2 and stored in -80C until all
time points were collected. Pellets were lysed on ice for
30min in a lysis buffer containing 1% Triton-X-100, 50
mM Hepes, 150 mM NaCl, 1.5 mM MgCl2, 1 mM EGTA,
10% glycerol, 100 mM NaF, 10 mM sodium pyrophos-
phate, 25 mM beta glycerol phosphate, 1 mM DTT, 1 mM
sodium vanadate, 1 mM benzamidine, 0.1 M okadaic
acid, 10 g/ml aprotinin, 10 g/ml leupeptin and protease
inhibitor cocktail (Sigma). The lysates were centrifuged at
14,000 at 4C for 30 min. The supernatants were aliquoted
and stored at -20C.
The in vitro kinase assay of GSK3 was conducted in 40 μl
of reaction mixture, which consisted of 75 μg of total pro-
tein, kinase reaction buffer (consisting of 10 mM 4-mor-
pholinepropanesulfonic acid pH 7.4, 1 mM EDTA, 10
mM Mg Acetate, 50 mM beta glycerol phosphate, 20 mM
MgCl2, 250 M cold ATP, 1 mM sodium vanadate, 0.5 mM
NaF, 0.1 M okadaic acid, 1 mM benzamidine, 1 mM DTT
and protease cocktail inhibitor), 62.5 mM phosphoglyco-
gen synthase peptide-2 (Upstate Biotechnology) or glyco-
gen synthase peptide-2 (Ala-21) (negative control for the
substrate). The reaction was started by the addition of 2.5
μCi of [γ-32P] ATP. The mixture was incubated at 30C for
30 min, and briefly centrifuged. 15 μl of supernatant was
spotted on Whatman P81 phosphocellulose paper. The
filters were washed gently in 0.75 % phosphoric acid three
times (5 min. each wash), and rinsed in acetone, dried
and counted in a liquid scintillation counter.
Phosphorylation assay of AKT/PKB
Cells were washed once with cold PBS and scraped, col-
lected in Eppendorf tubes and briefly centrifuged. PBS as
a supernatant was aspirated, the pellets were snap frozen
in liquid nitrogen, and stored at -80C until all the time
points were collected. The cells were lysed in lysis buffer
(0.5% NP40, 50 mM HEPES (pH 7.6), 200 mM NaCl, 1
mM EDTA, 20 mM NaF, 10 mM -glycerophosphate, 0.1
mM sodium orthovanadate, 10 g/ml benzamidine, 1 mM
PMSF and protease inhibitor cocktail (Sigma)) on ice for
30 min, followed by centrifugation in Eppendorf centri-
fuge (4C) at 14,000 rpm for 30 min. Supernatants were
aliquoted and stored at -20C. 30 μg of total protein was
run on a 10% SDS-PAGE gel and transferred onto a sup-
ported nitrocellulose membrane (Schleicher and Schuell)
for 30 min using a semidry transfer apparatus (BioRad).
The membrane was blocked for 1 hr at room temperature,
using either 5% non fat dry milk or 1% BSA in Tris buffer
saline containing 0.05 % tween-20 (TBST). It was then
incubated in the primary antibody in overnight at 4C. The
following dilutions were used for the primary antibodies:
anti-phospho AKT ps473 (1:500); anti-phospho GSK3
(1:500); anti-AKT (1:500); anti-GSK3 (1:2000). The
membrane was washed three times in TBST, 5 min per
wash and then incubated in AP-conjugated anti-mouse
IgG (1:1000) or anti-rabbit IgG (1:30,000) for 2 hours at
room temperature. Following three washes with TBST, the
blot was incubated with AP based fluorescent substrate
(Amersham Pharmacia Biotech) and the bands were visu-
alized and quantified by a fluorescence scanning instru-
ment such as Molecular Dynamics Stormimager.
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